BridgeBio Pharma Inc vs Trump Media and Technology Group Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Trump Media and Technology Group Corp trades at $8.3 (market cap $2.48B). The key difference: BridgeBio Pharma Inc is far larger — about 6.6× Trump Media and Technology Group Corp's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | DJT | |
|---|---|---|
Market Cap | $16.36B | $2.48B |
Sector | Health | Media |
52-Week High | $90.17 | $18.50 |
52-Week Low | $47.29 | $7.06 |
Enterprise Value | $18.14B | $2.54B |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
DJT stock trades at $8.38, down 10.81% in the last 24 hours, reflecting a bearish technical signal. The company reported Q2 2026 revenue of $1.67 million, up 89% year-over-year, but net losses widened to $238.1 million due to digital asset declines. The price-to-sales ratio of 547.62 indicates an extremely high valuation relative to minimal revenue, while negative profitability metrics and substantial cash burn persist.
The outlook remains highly speculative with significant risks from unsustainable losses and volatile digital asset holdings. Investment appeal is limited to high-risk tolerance given the lack of profitability and bearish analyst sentiment. Key catalysts include future revenue growth from new products like the Truth API, but current fundamentals do not support the valuation.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →